Gomez, Louis A.
Shen, Qi
Doyle, Kevin
Vrosgou, Athina
Velazquez, Angela
Megjhani, Murad
Ghoshal, Shivani
Roh, David
Agarwal, Sachin
Park, Soojin
Claassen, Jan
Kleinberg, Samantha http://orcid.org/0000-0001-6964-3272
Funding for this research was provided by:
U.S. National Library of Medicine (R01LM011826)
National Institute of Neurological Disorders and Stroke (R01NS106014)
Article History
Received: 23 February 2022
Accepted: 8 August 2022
First Online: 15 September 2022
Declarations
:
: Dr. Claassen is an iCE Neurosystems minority shareholder and on the Editorial Board of Neurocritical Care. Dr. Claassen also has received grant support from the James S. McDonnell Foundation and NINDS. Dr. Roh is consulting for Portola Pharmaceuticals and has grants from the Department of Defense and the National Blood Foundation Science. Dr. Roh also has an active role in the American Heart Association Hemorrhagic Stroke Science Committee. Dr. Park is an Associate Editor for Neurocritical Care and on the Board of Trustees for the Neurocritical Care Foundation. Dr. Park also has grants from the National Institutes of Health. Dr. Kleinberg has received royalties from O’Reilly Media and the Cambridge University Press. The remaining authors have disclosed that they do not have any conflict of interests.
: The data were collected as part of an institutional review board–approved study at Columbia University (approval numbers AAA5384 and AAAD4775). Patients provided informed consent when they were able to do so. Otherwise, a health care proxy or legally authorized representative did so. When there was no designated health care proxy or legally authorized representative and the patient was unable to provide informed consent, they were enrolled under a waiver of consent as long as a family member did not object. If a patient regained consciousness later, they provided consent or declined participation.